Zobrazeno 1 - 10
of 383
pro vyhledávání: ''
Publikováno v:
OncoTargets and therapy
Epidermal growth factor receptor (EGFR) fusions are rare genomic events in non-small-cell lung cancer (NSCLC). With advances in detection technology, some uncommon genomic mutation events, including EGFR fusions, have been detected. There are no stan
Publikováno v:
OncoTargets and therapy
Early T‐cell precursor acute lymphoblastic leukemia (ETP-ALL) is an aggressive and extremely fatal subtype of T-cell acute lymphoblastic leukemia (T-ALL), characterized by the similar transcriptional and immunophenotypic profiles to those of early
Publikováno v:
OncoTargets and therapy
EGFR-tyrosine kinase inhibitors (TKIs) have revolutionized the treatment for NSCLC. However, acquired drug resistance often occurs after treatment with EGFR-TKIs. EGFR T790M and C797S mutations are the most common resistance mechanism in patients who
Publikováno v:
OncoTargets and therapy
Approximately 70% of breast cancer (BC) cases are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have acted as star drugs for reversing endocrine t
Publikováno v:
OncoTargets and therapy
Dehui Fu, Chao Li, Yongwang Huang Department of Ear-Nose-Throat (ENT), The Second Hospital of Tianjin Medical University, Tianjin, 300211, People’s Republic of ChinaCorrespondence: Yongwang HuangDepartment of Ear-Nose-Throat, The Second Hospital of
Publikováno v:
OncoTargets and therapy
Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) complicated with angioimmunoblastic T-cell lymphoma (AITL) is extremely rare and typically shows an aggressive clinical course and unsatisfactory prognosis. Here, we describe t
Publikováno v:
OncoTargets and therapy
Cancer is one of the major threats to human health. Although humans have struggled with cancer for decades, the efficacy of treatments for most tumors is still very limited. Dihydroartemisinin (DHA) is a derivative of artemisinin, a first-line antima
Autor:
Ting Lei, Tong Zhao, Ruoyu Wang, Bin Yang, Yan Ding, Yuqin Tian, Bowen Tan, Xinjia Ding, Lin Liu, Jianlin Wu
Publikováno v:
OncoTargets and therapy
Multiple primary cancers (MPC) occurring in the same individual is considered rare but being increasingly recognized owing to the longer cancer survival nowadays. Despite of accumulating experience in diagnosis, effective treatment remains to be prob
Autor:
Hua Bao, Yuefei Cai, Ran Cao, Xue Shen Wu, Lu Zhang, Ping Yang, Liming Peng, Lingling Yang, Yang Shao, Weijun Zhang, Dongqin Zhu
Publikováno v:
OncoTargets and therapy
Background Drug resistance caused by G1202R/G1202del mutation in anaplastic lymphoma kinase (ALK) represents a great challenge in the clinic. The effect of other mutation(s) at G1202 on the available tyrosine kinase inhibitors (TKIs) in the clinic re
Publikováno v:
OncoTargets and therapy
Human epidermal growth factor receptor2 (HER2) overexpression/amplification is associated with high malignancy, rapid disease progression and poor overall survival in breast cancer. The application of anti-HER2 drugs has greatly improved the survival